Determining efficacy of breast cancer therapy by PET imaging of HER2 mRNA

Nuclear Medicine and Biology

Volumn 40, Issue 8, 2013, Pages 994-999

  Paudyal, Bishnuhari ^a   Zhang, Kaijun ^a   Chen, Chang Po ^a   Wampole, Matthew E ^a   Mehta, Neil ^a   Mitchell, Edith P ^a,b   Gray, Brian D ^c   Mattis, Jeffrey A ^c   Pak, Koon Y ^c   Thakur, Mathew L ^a,b   Wickstrom, Eric ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MOLECULAR TARGETING TECHNOLOGIES INC   (United States)

Author keywords

Breast cancer; Copper 64; Doxorubicin; HER2; Peptide nucleic acid

Indexed keywords

COPPER 64 TETRAXETAN WT 4340 PEPTIDE CU 64; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORODEOXYGLUCOSE F 18; MESSENGER RNA; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BREAST CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; GENE EXPRESSION; HER2 GENE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE QUALITY; MOLECULAR IMAGING; MOLECULAR WEIGHT; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; TUMOR VOLUME;

BREAST CANCER; COPPER-64; DOXORUBICIN; HER2; PEPTIDE NUCLEIC ACID;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; DOXORUBICIN; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MICE; PEPTIDE NUCLEIC ACIDS; POSITRON-EMISSION TOMOGRAPHY; RECEPTOR, ERBB-2; RNA, MESSENGER; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84886283772     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2013.08.005     Document Type: Article

References (23)

1. American Cancer Society breast cancer facts & figures 2012.
2. Avril N., Sassen S., Roylance R. Response to therapy in breast cancer. J Nucl Med 2009, 1:55S-63S.
3. Hanaoka H., Katagiri T., Fukukawa C., et al. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10: therapeutic efficacy largely depends on radiosensitivity. Ann Nucl Med 2009, 5:479-485.
4. Paudyal B., Paudyal P., Oriuchi N., Hanaoka, et al. Positron emission tomography imaging and biodistribution of vascular endothelial growth factor with Cu-64-labeled bevacizumab in colorectal cancer xenografts. Cancer Sci 2011, 102:117-121.
5. Paudyal P., Paudyal B., Hanaoka H., et al. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET. Cancer Sci 2010, 101:1045-1050.
6. Wu C.Y., Chou L.S., Chan P.C., et al. Monitoring tumor response with radiolabeled nucleoside analogs in a hepatoma-bearing mouse model early after Doxisome (®) treatment. Mol Imaging Biol 2013, 15:326-335.
7. Schwarz J.K., Grigsby P.W., Dehdashti F., et al. The role of F-18-FDG PET in assessing therapy response in cancer of the cervix and ovaries. J Nucl Med 2009, 50:64S-73S.
8. Tomasi G., Rosso L. (2012) PET imaging: implications for the future of therapy monitoring with PET/CT in oncology. Curr Opin Pharmacol 2009, 12:569-575.
9. 99mTc-peptide nucleic acid-peptide chimeras. J Nucl Med 2004, 45:2070-2082.
10. 99mTc] peptide-peptide nucleic acid-peptide chimera. Bioconj Chem 2005, 16:70-79.
11. Tian X., Aruva M.R., Zhang K., et al. PET imaging of CCND1 mRNA in human MCF7 estrogen receptor-positive breast cancer xenografts with an oncogene specific [Cu-64] DO3A-PNA-peptide radiohybridization probe. J Nucl Med 2007, 48:1699-1707.
12. 111)In]DOTA(n)-poly(diamidopropanoyl)(m)-KRAS2 PNA-D(Cys-Ser-Lys-Cys) nanoparticles. Bioconjug Chem 2010, 21:731-740.
13. Egholm M., Buchardt O., Christensen L., et al. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature 1993, 365:566-568.
14. Good L., Nielsen P.E. Progress in developing PNA as a gene-targeted drug. Antisense Nucleic Acid Drug Dev 1997, 7:431-437.
15. Thakur M.L., Devadhas D., Zhang K., et al. Imaging spontaneous MMTVneu transgenic murine mammary tumors: targeting metabolic activity versus genetic products. J Nucl Med 2010, 51:106-111.
16. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998, 3:237-252.
17. Cobleigh M.A., Vogel C.L., Tripathy N.J., et al. Multinational study of the efficacy and safety of humanized anti-Her2 monoclonal antibody in women who have Her2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
18. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against Her2 for metastatic breast cancer that overexpresses Her2. N Engl J Med 2001, 344:783-792.
19. Bertram J., Killian M., Brysch W., et al. Reduction of erbB2 gene product in mamma carcinoma cell lines by erbB2 mRNA-specific and tyrosine kinase consensus phosphorothioate antisense oligonucleotides. Biochem Biophys Res Commun 1994, 200:661-667.
20. Vaughn J.P., Stekler J., Demirdji S., et al. Inhibition of the erbB-2 tyrosine kinase receptor in breast cancer cells by phosphoromonothioate and phosphorodithioate antisense oligonucleotides. Nucleic Acids Res 1996, 24:4558-4564.
21. Muller W.J., Arteaga C.L., Muthuswamy S.K., et al. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice. Mol Cell Biol 1996, 16:5726-5736.
22. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia 2000, 5:95-105.
23. Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 1998, 152:63-70.